Andrew Phillips is a Senior Director at AbbVie, leading the Oncology Discovery ADC team since January 2013 and responsible for overall antibody-drug conjugate (ADC) strategy and clinical development programs. Prior roles at AbbVie include Director and Research Fellow, focusing on developing novel ADC technology and guiding programs like BCL-XL inhibitor and topoisomerase inhibitor ADCs into clinical pipelines. As Project Director, Andrew built and led teams to transition biologics programs from discovery to clinical development, while also serving as Senior Group Leader, managing multiple oncology biologics programs that advanced to clinical trials. Earlier experience includes serving as Group Leader at Abbott and as an Assistant Professor at the Medical College of Georgia at Georgia Regents University. Andrew Phillips earned a PhD in Cancer Biology from the University of Glasgow from 1989 to 1994.
This person is not in any teams
This person is not in any offices